Predicted protein targets (top 18)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CYP2C19 | P33261 | 2/20 | 0.43 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.43 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.43 |
| ▸ | ALOX5 | P09917 | 1/20 | 0.41 |
| ▸ | MAPT | P10636 | 3/20 | 0.39 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.39 |
| ▸ | HPGD | P15428 | 2/20 | 0.39 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.39 |
| ▸ | RECQL | P46063 | 1/20 | 0.38 |
| ▸ | EPHX2 | P34913 | 1/20 | 0.38 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.37 |
| ▸ | RAB9A | P51151 | 2/20 | 0.37 |
| ▸ | NPC1 | O15118 | 1/20 | 0.37 |
| ▸ | HTT | P42858 | 1/20 | 0.37 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.37 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.36 |
| ▸ | GLA | P06280 | 1/20 | 0.36 |
| ▸ | GAA | P10253 | 1/20 | 0.36 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL8904079 | 0.72 | CES2 (0.42) | CYP2C19L3MBTL1ALOX5MAPTALDH1A1 | |
| Phenylethylmalonamide SCHEMBL341785 | 0.71 | MAPT (0.55) | CYP2C19MAPTKMT2AHTTKDM4E | |
| Phenylethylmalonamide SCHEMBL29755357 | 0.70 | MAPT (0.53) | CYP2C19MAPTKMT2AHTTKDM4E | |
| SCHEMBL1644668 | 0.69 | ALDH1A1 (0.44) | CYP2C19CYP3A4L3MBTL1ALOX5MAPT | |
| Phenylethylmalonamide - SCHEMBL7828223 | 0.69 | KMT2A (0.52) | CYP2C19MAPTALDH1A1KMT2AHTT | |
| SCHEMBL17240907 | 0.68 | ALOX5 (0.49) | CYP2C19CYP3A4L3MBTL1ALOX5MAPT | |
| Acetic Acid SCHEMBL30128630 | 0.68 | ALOX5 (0.45) | CYP2C19CYP3A4L3MBTL1ALOX5MAPT | |
| SCHEMBL12286073 | 0.67 | ALOX5 (0.51) | CYP2C19CYP3A4L3MBTL1ALOX5MAPT | |
| SCHEMBL29008162 | 0.67 | L3MBTL1 (0.53) | CYP2C19L3MBTL1ALOX5MAPTALDH1A1 | |
| SCHEMBL28430563 | 0.67 | MAPT (0.53) | CYP2C19L3MBTL1ALOX5MAPTALDH1A1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 24 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20240180878-A1 | AMIDE DERIVATIVES OF BUTYRIC ACID FOR USE IN THE TREATMENT OR PREVENTION OF SARS-COV-2 INFECTION | RHEA INNOVATIONS S.R.L. (IT) | 2024-06-06 | — | — | US | claimed |
| EP-4322935-A1 | AMIDE DERIVATIVES OF BUTYRIC ACID FOR USE IN THE TREATMENT OR PREVENTION OF SARS-COV-2 INFECTION | Rhea Innovations S.R.L. (IT) | 2024-02-21 | — | — | EP | claimed |
| WO-2022219020-A1 | AMIDE DERIVATIVES OF BUTYRIC ACID FOR USE IN THE TREATMENT OR PREVENTION OF SARS-COV-2 INFECTION | RHEA INNOVATIONS S.R.L. (IT) | 2022-10-20 | — | — | WO | claimed |
| US-10034937-B2 | Synergistic nutritional compositions and uses thereof | MEAD JOHNSON NUTRITION COMPANY (US) | 2018-07-31 | — | — | US | claimed |
| US-20170215464-A1 | NUTRITIONAL COMPOSITIONS CONTAINING DIETARY BUTYRATE AND USES THEREOF | MEAD JOHNSON NUTRITION COMPANY | 2017-08-03 | — | — | US | claimed |
| US-20170157242-A1 | SYNERGISTIC NUTRITIONAL COMPOSITIONS AND USES THEREOF | MEAD JOHNSON NUTRITION COMPANY | 2017-06-08 | — | — | US | claimed |
| US-20170127693-A1 | NUTRITIONAL COMPOSITIONS CONTAINING BUTYRATE AND USES THEREOF | MEAD JOHNSON NUTRITION COMPANY | 2017-05-11 | — | — | US | claimed |
| US-9255062-B2 | Fatty acid derivatives for oral administration endowed with high palatability | RHEA INNOVATIONS S.R.L. (IT) | 2016-02-09 | — | — | US | claimed |
| EP-2268605-B1 | FATTY ACID DERIVATIVES FOR ORAL ADMINISTRATION ENDOWED WITH HIGH PALATABILITY | BERNI CANANI ROBERTO (IT) | 2014-06-04 | — | — | EP | claimed |
| US-20110098319-A1 | FATTY ACID DERIVATIVES FOR ORAL ADMINISTRATION ENDOWED WITH HIGH PALATABILITY | RHEA INNOVATIONS S.R.L. (IT) | 2011-04-28 | — | — | US | claimed |
| EP-2268605-A1 | FATTY ACID DERIVATIVES FOR ORAL ADMINISTRATION ENDOWED WITH HIGH PAIA- TABILITY | Berni Canani, Roberto (IT) | 2011-01-05 | — | — | EP | claimed |
| WO-2009130735-A1 | FATTY ACID DERIVATIVES FOR ORAL ADMINISTRATION ENDOWED WITH HIGH PALATABILITY | BERNI CANANI ROBERTO (IT) | 2009-10-29 | — | — | WO | claimed |
| US-20240180878-A1 | AMIDE DERIVATIVES OF BUTYRIC ACID FOR USE IN THE TREATMENT OR PREVENTION OF SARS-COV-2 INFECTION | RHEA INNOVATIONS S.R.L. (IT) | 2024-06-06 | — | — | US | disclosed |
| EP-4322935-A1 | AMIDE DERIVATIVES OF BUTYRIC ACID FOR USE IN THE TREATMENT OR PREVENTION OF SARS-COV-2 INFECTION | Rhea Innovations S.R.L. (IT) | 2024-02-21 | — | — | EP | disclosed |
| WO-2022219020-A1 | AMIDE DERIVATIVES OF BUTYRIC ACID FOR USE IN THE TREATMENT OR PREVENTION OF SARS-COV-2 INFECTION | RHEA INNOVATIONS S.R.L. (IT) | 2022-10-20 | — | — | WO | disclosed |
| US-10034937-B2 | Synergistic nutritional compositions and uses thereof | MEAD JOHNSON NUTRITION COMPANY (US) | 2018-07-31 | — | — | US | disclosed |
| EP-2268605-B1 | FATTY ACID DERIVATIVES FOR ORAL ADMINISTRATION ENDOWED WITH HIGH PALATABILITY | BERNI CANANI ROBERTO (IT) | 2014-06-04 | — | — | EP | disclosed |
| US-20110098319-A1 | FATTY ACID DERIVATIVES FOR ORAL ADMINISTRATION ENDOWED WITH HIGH PALATABILITY | RHEA INNOVATIONS S.R.L. (IT) | 2011-04-28 | — | — | US | disclosed |
| EP-2268605-A1 | FATTY ACID DERIVATIVES FOR ORAL ADMINISTRATION ENDOWED WITH HIGH PAIA- TABILITY | Berni Canani, Roberto (IT) | 2011-01-05 | — | — | EP | disclosed |
| WO-2009130735-A1 | FATTY ACID DERIVATIVES FOR ORAL ADMINISTRATION ENDOWED WITH HIGH PALATABILITY | BERNI CANANI ROBERTO (IT) | 2009-10-29 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20110098319-A1 | FATTY ACID DERIVATIVES FOR ORAL ADMINISTRATION ENDOWED WITH HIGH PALATABILITY | FABP2, FFAR2, VIP | CYP2C19 938/4885CYP3A4 679/4885L3MBTL1 1833/4885 |
| US-10034937-B2 | Synergistic nutritional compositions and uses thereof | FABP2, LRBA, TSLP | CYP2C19 1010/4885CYP3A4 924/4885L3MBTL1 2947/4885 |
| US-20170157242-A1 | SYNERGISTIC NUTRITIONAL COMPOSITIONS AND USES THEREOF | FABP2, LRBA, TSLP | CYP2C19 1010/4885CYP3A4 924/4885L3MBTL1 2947/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.